Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Spatially controlled tenascin-C accumulation contributes to inflammatory disease persistence in giant cell aortitis
Hui Shi, Ying Tang, Jing Li, Ora Gewurz-Singer, Bo Yang, Dogukan Mizrak
Hui Shi, Ying Tang, Jing Li, Ora Gewurz-Singer, Bo Yang, Dogukan Mizrak
View: Text | PDF
Research Article Inflammation Vascular biology

Spatially controlled tenascin-C accumulation contributes to inflammatory disease persistence in giant cell aortitis

  • Text
  • PDF
Abstract

Giant cell aortitis (GCA) is an inflammatory disease of the aortic wall with a characteristic giant cell pattern on pathology and can lead to life-threatening aortic aneurysm and dissection. Pathogenic GCA mechanisms underlying aortic inflammation and persistence remain elusive. Here, we demonstrate the complexity of medial layer destruction and immune cell infiltration in clinical granulomatous GCA and lymphoplasmacytic IgG4-related aortitis samples using imaging-based gene expression profiling. Single-cell spatial profiling revealed aortic wall remodeling in the GCA aortas, highlighting substantial phenotypic modulation in stromal cells, including vascular smooth muscle cells (SMCs) and fibroblasts. Specifically, we observed the expansion of stromal cells expressing Tenascin-C (TNC) mRNA and spatially refined TNC accumulation in lesion areas. We confirmed these findings histologically using diseased aortas resected from individuals with giant cell arteritis and clinically isolated aortitis. Mechanistically, our data suggest that TNC promotes a proinflammatory phenotype in primary human SMCs, elevating IL-6 levels partially through the TLR4/NF-κB pathway. IL-6 signaling propagates the proinflammatory loop by activating STAT3. Pharmacological blockade of the IL-6 receptor using tocilizumab alleviated the TNC-driven proinflammatory phenotype. We propose that TNC acts as a local catalyst of inflammatory disease persistence mainly via IL-6 signaling activation and offers a potential avenue for sustained disease remission.

Authors

Hui Shi, Ying Tang, Jing Li, Ora Gewurz-Singer, Bo Yang, Dogukan Mizrak

×

Figure 4

Tenascin-C is a local catalyst of inflammation.

Options: View larger image (or click on image) Download as PowerPoint
Tenascin-C is a local catalyst of inflammation.
(A) Relative expression ...
(A) Relative expression of SMC and inflammatory markers in primary SMCs overexpressing a control or TNC plasmid (n = 6, unpaired t test, unpaired t test with Welch’s correction, or Mann-Whitney test). (B) Relative expression of SMC and inflammatory markers in primary SMCs treated with Control-CM or TNC-CM (n = 6, unpaired t test or unpaired t test with Welch’s correction). (C) Immunofluorescence for p-NF-κB and α-SMA on primary cells after TNC-CM and TAK-242 (TLR4 inhibitor) treatments. Scale bars: 50 μm. (D) Western blots showing the levels of SMC markers after TNC-CM and TAK-242 treatments and their quantification (n = 3, 1-way ANOVA or Kruskal-Wallis test with multiple comparisons). (E) Quantification of IL-6, IL-1β, and CCL2 ELISAs on the conditioned media after Control-CM, TNC-CM, and TAK-242 treatments (n = 6, Brown-Forsythe and Welch’s ANOVA with multiple comparisons). (F) Relative expression of SMC and proinflammatory cytokines in primary SMCs treated with IL-6, soluble IL-6 receptor (sIL6R), and tocilizumab (TCZ) (n = 6, 1-way ANOVA, Brown-Forsythe and Welch’s ANOVA or Kruskal-Wallis test with multiple comparisons). (G) Quantification of MYH11 and CNN1 immunoblots after IL-6 signaling activation and blockade by TCZ (n = 3, 1-way ANOVA with multiple comparisons). (H) Western blots for MYH11 and CNN1 after Control-CM, TNC-CM, TCZ, and TAK-242 treatments. (I) Quantification of MYH11 and CNN1 Western blots (n = 3, 1-way ANOVA with multiple comparisons). (J) Quantification of IL-6, IL-1β, and CCL2 ELISAs in the conditioned media after Control-CM, TNC-CM, TCZ, and TAK-242 treatments (n = 6, 1-way ANOVA with multiple comparisons).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts